Antimicrobial resistance in northern Australia: the HOTspots surveillance and response program annual epidemiology report 2022
DOI:
https://doi.org/10.33321/cdi.2025.49.030Keywords:
antimicrobial resistance, surveillance, northern Australia, regional, communityAbstract
Background
The HOTspots surveillance and response program monitors antimicrobial resistance (AMR) in selected bacterial pathogens across three jurisdictions in northern Australia. In 2022, the program collected data from 164 community healthcare clinics and 50 hospitals to assess AMR trends and geographic variations.
Methods
Data on resistance rates for methicillin-resistant Staphylococcus aureus (MRSA) and for Escherichia coli (E. coli) were analysed. Geographic regions were compared to identify variations in AMR across the Northern Territory, northern Western Australia and northern Queensland. Resistance rates were compared between community clinics and hospitals.
Findings
In 2022, there were 56,003 clinical isolates submitted to HOTspots. Geographic variation was evident in S. aureus methicillin resistance, with MRSA accounting for 14.4% of S. aureus isolates in the east, 53.1% in central northern Australia and 46.3% in western northern Australia. Clindamycin-resistant MRSA was highest in the Northern Territory (21.7%) compared to Western Australia (16.1%) and Queensland (5.9%), limiting treatment options for community-acquired MRSA. Ceftriaxone-resistant E. coli also varied geographically, with resistance rates ranging from 3.9% in the east to 23.4% in central and 10.1% in the west. High rates of ceftriaxone resistance were observed in both community clinics (10.6%) and hospitals (16.3%). Nitrofurantoin-resistant E. coli remained low (0.2%) and stable over the past five years.
Interpretation
HOTspots data are critical for informing local antibiotic guidelines and aiding clinical decision-making. This detailed surveillance captures geographic and healthcare-setting-specific variations in AMR, which can improve regional treatment strategies across northern Australia, with a focus on the Northern Territory, which had previously lacked comprehensive surveillance.
Downloads
References
Wozniak TM, Smith-Vaughan H, Andrews R. Convergence of surveillance blind spots with antimicrobial resistance hotspots. Aust N Z J Public Health. 2021;45(6):541–2. doi: https://doi.org/10.1111/1753-6405.13165.
Wozniak TM, Cuningham W, Buchanan S, Coulter S, Baird RW, Nimmo GR et al. Geospatial epidemiology of Staphylococcus aureus in a tropical setting: an enabling digital surveillance platform. Sci Rep. 2020;10(1):13169. doi: https://doi.org/10.1038/s41598-020-69312-4.
Goddard L, Wozniak TM. Antimicrobial resistance surveillance to support decision-making in a high-prevalence region: an evaluation. Front Trop Dis. 2021;2. doi: https://doi.org/10.3389/fitd.2021.772491.
Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2021: Fourth Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2021. Available from: https://www.safetyandquality.gov.au/sites/default/files/2021-09/aura_2021_-_report_-_final_accessible_pdf_-_for_web_publication.pdf.
ACSQHC. AURA 2023: Fifth Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 16 November 2023. Available from: https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-aura/aura-2023-fifth-australian-report-antimicrobial-use-and-resistance-human-health.
ACSQHC. Specification for a Hospital Cumulative Antibiogram. Sydney: ACSQHC; December 2019. Available from: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/specification-hospital-cumulative-antibiogram-2019.
Central Australian Rural Practitioners Association (CARPA) Editorial Committee. CARPA Standard Treatment Manual (8th edition). Alice Springs: Centre for Remote Health; 2022. [Accessed in May 2023.] Available from: https://remotephcmanuals.com.au/home.html.
Northern Territory Primary Health Network (NT PHN). Northern Territory HealthPathways. [Website.] DarwinL NT PHN; 2022. Available from: https://www.ntphn.org.au/health-professionals-hub/nt-healthpathways/.
HOT NORTH. HOT NORTH Antimicrobial Academy 2022 Program. Darwin: Royal Darwin Hospital/Menzies School of Health Research, HOT NORTH; 2022. Available from: https://www.naccho.org.au/app/uploads/2022/06/HNAA_2022_Program.pdf.
Wozniak TM, Dyda A, Merlo G, Hall L. Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia. Lancet Reg Health West Pac. 2022;27:100521. doi: https://doi.org/10.1016/j.lanwpc.2022.100521.
Wozniak TM, Dyda A, Lee X. The increased length of hospital stay and mortality associated with community-associated infections in Australia. Open Forum Infect Dis. 2022;9(5):ofac133. doi: https://doi.org/10.1093/ofid/ofac133.
Wozniak TM, Cuningham W, Ledingham K, McCulloch K. Contribution of socio-economic factors in the spread of antimicrobial resistant infections in Australian primary healthcare clinics. J Glob Antimicrob Resist. 2022;30:294–301. doi: https://doi.org/10.1016/j.jgar.2022.06.005.
Cuningham W, Perera S, Coulter S, Nimmo GR, Yarwood T, Tong SYC et al. Antibiotic resistance in uropathogens across northern Australia 2007–20 and impact on treatment guidelines. JAC Antimicrob Resist. 2021;3(3):dlab127. doi: https://doi.org/10.1093/jacamr/dlab127.
(a) Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. doi: https://doi.org/10.1016/S0140-6736(21)02724-0. (b) ibid. (Erratum). Lancet. 2022;400(10358):1102. doi: https://doi.org/10.1016/S0140-6736(21)02653-2.
Babu Rajendran N, Arieti F, Mena-Benítez CA, Galia L, Tebon M, Alvarez J et al. EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data: a Delphi approach. Lancet Reg Health Eur. 2022:26;100563. doi: https://doi.org/10.1016/j.lanepe.2022.100563.
Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS). [Online resource.] Canberra: Australian Bureau of Statistics; 2021. [Accessed in May 2023.] Available from: https://www.abs.gov.au/statistics/statistical-geography/australian-statistical-geography-standard-asgs.
Clinical and Laboratory Standard Institute (CLSI). M100 – Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition. Wayne, PA: CLSI; 29 March 2021. [Accessed in May 2023.] Available from: https://clsi.org/about/press-releases/clsi-publishes-m100-performance-standards-for-antimicrobial-susceptibility-testing-31st-edition/.
World Health Organization (WHO) Global Antimicrobial Resistance Surveillance System (GLASS). GLASS report: early implementation 2016–2017. Geneva: WHO, GLASS; 29 January 2018. Available from: https://www.who.int/publications/i/item/9789241513449.
ACSQHC. Australian Passive AMR Surveillance (APAS). [Webpage.] Sydney: ACSQHC; 2024. Available from: https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-aura/hospital-and-community-antimicrobial-resistance/australian-passive-amr-surveillance-apas.
Queensland Government, Office of the Queensland Parliamentary Counsel. Public Health Act 2005. [Legislation.] Brisbane: Queensland Government; 2023. [Accessed in May 2023.] Available from: https://www.legislation.qld.gov.au/view/html/inforce/current/act-2005-048.
Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y et al. Clinical impact of ceftriaxone resistance in Escherichia coli bloodstream infections: a multicenter prospective cohort Study. Open Forum Infect Dis. 2022;9(11):ofac572. doi: https://doi.org/10.1093/ofid/ofac572.
Rolfe RJ, Shaikh H, Tillekeratne LG. Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks. Infect Dis Poverty. 2022;11(1):77. doi: https://doi.org/10.1186/s40249-022-00998-6.
McGuinness SL, Holt DC, Harris TM, Wright C, Baird R, Giffard PM et al. Clinical and molecular epidemiology of an emerging Panton-Valentine leukocidin-positive ST5 methicillin-resistant Staphylococcus aureus clone in northern Australia. mSphere. 2021;6(1):e00651-20. doi: https://doi.org/10.1128/msphere.00651-20.
CARPA Editorial Committee. CARPA Standard Treatment Manual (7th edition). Alice Springs: Centre for Remote Health; 2017. [Accessed in May 2023.] Available from: https://remotephcmanuals.com.au/.
Cuningham W, Anderson L, Bowen AC, Buising K, Connors C, Daveson K et al. Antimicrobial stewardship in remote primary healthcare across northern Australia. PeerJ. 2020;8:e9409. doi: https://doi.org/10.7717/peerj.9409.
Therapeutic Guidelines (eTG). Antibiotic (version 16). [Webpage.] West Melbourne: Therapeutic Guidelines Limited; 2019. Available from: https://app.tg.org.au/viewTopic?guidelinePage=Antibiotic&etgAccess=true.
Australian Institute of Health and Welfare (AIHW). Hospitals info and downloads: Glossary. [Webpage.] Canberra: Australian Government, AIHW; 2023. Available from: https://www.aihw.gov.au/reports-data/myhospitals/content/glossary#:~:text=Hospital%3A%20A%20health%20care%20facility,and%2For%20care%20to%20patients.
Published
How to Cite
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
